Work for Aeglea BioTherapeutics, Inc.?

Claim Your Profile

Aeglea BioTherapeutics, Inc. Logo Image

Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc. has reached its limit for free report views.

About Aeglea BioTherapeutics, Inc.

51-200 Employees
Based in Austin, Texas

Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead product candidate, for the treatment of Arginase 1 Deficiency which has received both Rare Pediatric Disease and Breakthrough Therapy Designation. Aeglea has two programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline.

Ticker:
AGLE
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol